Incorporating of Biosimilars into Oncology Practice: Challenges and Opportunities for Clinicians

October 9th, 2019 - October 9th, 2020


This activity will share with learners the science behind biosimilars.  As biosimilar science is evolving rapidly, it is expected that these therapies will be increasingly used in oncology practice by multidisciplinary, collaborative teams of prescribers, pharmacists and patients.  Biosimilars are a distinct entity from other generic drugs, and participants with learn about naming conventions, manufacturing, the FDA regulatory approval process, and best practices related to biosimilar drug use. 

Target Audience
This CME initiative will target oncology nurse practitioners, physician assistants, pharmacists, and nurse specialties working in all phases of oncology care.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Review the key differences between biosimilars and generic drugs including pharmacologic properties, product naming, and required data needed for approval.

  • Describe current barriers in prescribing biosimilars for patients with cancer. 

  • Discuss the use and role of currently approved biosimilars in oncology practice and their potential impact on patient outcomes. 

  • Develop strategies and opportunities to incorporate currently available biosimilars into clinical practice for the treatment of oncology patients.

  • Assess biosimilars currently in Phase 3 development and their potential impact on oncology practice. 

Activity Launch Date - 10/9/2019
Expiration Date - 10/9/2020

Supporter Acknowledgment Statement
Supported by an independent medical educational grant from Sandoz, Inc., a Novartis Division.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Statement of Independence
Horizon CME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies.  It is the mission of Horizon CME to develop and present educational activities that are timely, fair balanced, scientifically rigorous, and that serve to improve patient outcomes.  To that end, we welcome comments about how to better serve your needs.

Copyright Information
© 2019 - All rights reserved. This CME-certified program is held as copyrighted by Horizon CME. Through this notice, Horizon CME grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.